Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Key facts

Sponsor

Icahn School of Medicine at Mount Sinai

Principal Investigator

Annetine C Gelijns, PhD

Icahn School of Medicine at Mount Sinai

Intervention

Antiplatelet-only strategy(drug)

Eligibility

18 years · All sexes

Timeline

2019 – 2026

Study locations (20)

• CHI St. Vincent, Arkansas, Little Rock, Arkansas, United States
• University of Southern California, Los Angeles, California, United States
• Cedars-Sinai Medical Center, Los Angeles, California, United States
• Stanford University, Stanford, California, United States
• Medical Center of Aurora, Aurora, Colorado, United States
• Western Connecticut Hospital Systems, Danbury, Connecticut, United States
• Yale Medicine, New Haven, Connecticut, United States
• MedStar Washington Hospital Center, Washington D.C., District of Columbia, United States
• Emory University, Atlanta, Georgia, United States
• Piedmont Healthcare Inc., Atlanta, Georgia, United States
• Lutheran Medical Center, Fort Wayne, Indiana, United States
• Indiana University, Indianapolis, Indiana, United States
• Ascension St. Vincent, Indianapolis, Indiana, United States
• Ochsner Clinic, New Orleans, Louisiana, United States
• Maine Medical Center, Portland, Maine, United States
• +5 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hereditary atrial fibrillation

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06578104
  PULSED AF Post-Approval Study
  Medtronic Cardiac Ablation Solutions
• RECRUITINGNANCT05951101
  Zenith LAA Occlusion System
  AuriGen Medical Ltd
• RECRUITINGNCT05190679
  Prospective Phenotyping for Genetic Subtypes of Early-onset Atrial Fibrillation
  Vanderbilt University Medical Center

See all trials for Hereditary atrial fibrillation →